Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomePreferred Shares IssuedShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Gains from Investment Securities: 2013-2024

Historic Gains from Investment Securities for vTv Therapeutics (VTVT) over the last 11 years, with Dec 2024 value amounting to $100,000.

  • vTv Therapeutics' Gains from Investment Securities fell 13.33% to -$34,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $87,000, marking a year-over-year decrease of 97.88%. This contributed to the annual value of $100,000 for FY2024, which is 97.64% down from last year.
  • Per vTv Therapeutics' latest filing, its Gains from Investment Securities stood at $100,000 for FY2024, which was down 97.64% from $4.2 million recorded in FY2023.
  • In the past 5 years, vTv Therapeutics' Gains from Investment Securities registered a high of $7.1 million during FY2021, and its lowest value of $100,000 during FY2024.
  • In the last 3 years, vTv Therapeutics' Gains from Investment Securities had a median value of $200,000 in 2022 and averaged $1.5 million.
  • Per our database at Business Quant, vTv Therapeutics' Gains from Investment Securities skyrocketed by 2,022.50% in 2023 and then slumped by 97.64% in 2024.
  • vTv Therapeutics' Gains from Investment Securities (Yearly) stood at $4.5 million in 2020, then spiked by 58.44% to $7.1 million in 2021, then slumped by 97.17% to $200,000 in 2022, then skyrocketed by 2,022.50% to $4.2 million in 2023, then tumbled by 97.64% to $100,000 in 2024.